NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/07/2022
Back to search
Official data from USPTO
S SEBELA PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
06/07/2022
Trademark type
Combined
Nice classes
5
Filing date
03/03/2020
Registration date
06/07/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/07/2022
Last transaction
06/07/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
11
Owner location
Dublin, IE
Examiner
FLETCHER, TRACY L
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "SEBELA" in turquoise above the word "PHARMACEUTICALS" in grey, appearing to the right of a stylized reverse letter "S" with a horizontal line and three dots all in grey.
Holders and representatives
Holders
Sebela Ireland Limited
Representatives
Jeffrey H. Handelsman GREENBLUM & BERNSTEIN, P.L.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in treating dermatologygastroenterologyrheumatologypsychiatric disorders; Pharmaceutical preparations for use in the treatment of pain and inflammation; Pharmaceutical preparations directed to women's health for use in the treatmentalleviation and prevention of thermoregulatory dysfunctions and vasomotor symptoms including hot flasheshot flushesnight awakeningsnight sweatssuch disorders and conditions associated with perimenopausemenopause and hormonal deficiencies; Menstrual symptom treatment preparations; Pharmaceutical preparations for use in treating nephrologyneurologyoncologyurologyandrology and cardiology diseases and disordersfor use in the treatment of nasal allergiesrespiratory allergiesfor use as anti-infectives; contraceptive preparations; dietary and nutritional supplements; prenatal vitamins; pharmaceutical preparations for the treatment of bone diseases; preparations for the suppression of hormones; pharmaceutical preparations directed to women's health for use in the treatmentalleviation and prevention of overactive bladderfemale sexual dysfunctioninfertilityendometriosisvaginitisosteoporosisosteopeniapelvic paindyspareuniacandidiasis; Diagnostic agentspreparations and substances for medical purposes; all of the aforesaid goods not for use as a product name of a pharmaceutical product
Publications
History of USPTO decisions and trademark events.
28 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/07/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/22/2022
PUBO
PUBLISHED FOR OPPOSITION
03/22/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/02/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/17/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
09/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/07/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/05/2021
GNRT
NON-FINAL ACTION E-MAILED
03/05/2021
CNRT
NON-FINAL ACTION WRITTEN
03/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/04/2021
ALIE
ASSIGNED TO LIE
03/02/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/02/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/21/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/21/2020
CNSI
SUSPENSION INQUIRY WRITTEN
11/21/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/21/2020
GNSL
LETTER OF SUSPENSION E-MAILED
05/21/2020
CNSL
SUSPENSION LETTER WRITTEN
05/21/2020
DOCK
ASSIGNED TO EXAMINER
05/21/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/09/2020
NWAP
NEW APPLICATION ENTERED
03/06/2020
Continuous trademark protection
Get notified about every new filing that threatens S SEBELA PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.